SCHEMBL29348805

SCHEMBL29348805

O=C(CCCCBr)NC1(c2ccc(Br)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 8/20 0.44
HDAC8 Q9BY41 4/20 0.44
NR1I2 O75469 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
CYP2D6 P10635 1/20 0.38
CHRM1 P11229 1/20 0.38
DRD2 P14416 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
CHRM3 P20309 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2A P28223 1/20 0.38
SLC6A4 P31645 1/20 0.38
ADRA1A P35348 1/20 0.38
HRH1 P35367 1/20 0.38
OPRM1 P35372 1/20 0.38
DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5738000 0.78 SMN1; SMN2 (0.47) HDAC1OPRM1RAB9A
SCHEMBL20898401 0.77 FPR3 (0.40) HDAC1SLC6A2SLC6A4SLC6A3HRH3
SCHEMBL2720873 0.74 MAPK1 (0.38) HDAC1HDAC2HDAC6HDAC3MAOA
SCHEMBL1697725 0.73 CYP1A2 (0.47) HDAC1CYP1A2DRD2DRD3HDAC2
SCHEMBL4654699 0.71 MEN1 (0.63) HDAC1HDAC8HDAC2HDAC5HDAC6
SCHEMBL14672673 0.70 GAA (0.41) HDAC1OPRM1SLC6A3HDAC2HDAC6
SCHEMBL22479429 0.70 MEN1 (0.61) HDAC1HDAC8NR1I2CYP3A4KCNH2
SCHEMBL17320670 0.70 HSD17B10 (0.46) HDAC1OPRM1RAB9A
SCHEMBL20898569 0.70 WDR91 (0.39) RAB9A
SCHEMBL22463794 0.69 KMT2A (0.66) HDAC1HDAC8HDAC2HDAC5HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4648853-A1 TARGETED DEGRADATION OF VAV1 Monte Rosa Therapeutics AG (CH) 2025-11-19 EP disclosed
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-06-26 US disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 VAV1, KRAS, CBL HDAC1 1607/4885HDAC8 1572/4885NR1I2 3506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.